Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3532 | RELX ENDS Tobacco Flavor Wiki | 1.00 |
drug5133 | placebo for clazakizumab Wiki | 0.71 |
drug903 | Candesartan Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
drug4592 | Usual Brand Cigarette Wiki | 0.71 |
drug4414 | Thromboprophylaxis Wiki | 0.71 |
drug4176 | Subject Usual Brand ENDS Wiki | 0.71 |
drug2794 | Nicorette White Ice Mint nicotine polacrilex gum Wiki | 0.71 |
drug3624 | Rehabilitation exercise protocol Wiki | 0.71 |
drug5092 | non-RAS blocking antihypertensives Wiki | 0.71 |
drug594 | Best standard of care Wiki | 0.71 |
drug978 | Chloroquine or Hydroxychloroquine Wiki | 0.41 |
drug2381 | Lopinavir/Ritonavir Wiki | 0.35 |
drug3715 | Rivaroxaban Wiki | 0.29 |
drug997 | Clazakizumab Wiki | 0.27 |
Navigate: Correlations HPO
There are 2 clinical trials
This study is being conducted to evaluate nicotine uptake, the potential abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system (ENDS) with tobacco- and menthol-flavored e-liquids in current ENDS consumers.
Description: PK Session baseline-adjusted maximum plasma nicotine concentration [Cmax]
Measure: Nicotine uptake Time: 120 minutesDescription: PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-120)]
Measure: Nicotine uptake Time: 120 minutesDescription: PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-15)]
Measure: Nicotine uptake - PK Session Time: 15 minutesDescription: PK Session time of the maximum post-baseline nicotine concentration [Tmax]
Measure: Nicotine uptake - PK Session Time: 120 minutesDescription: Ad Libitum Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-480)]
Measure: Nicotine uptake - Ad Libitum Session Time: 480 minutesDescription: Subjective product assessments during the Ad Libitum Session as measured by responses to the Modified Product Evaluation Scale (scale range of 1 [not at all] to 7 [extremely])
Measure: Subject effects as measured by the Modified Product Evaluation Scale Time: 480 minutesDescription: Subjective product assessments during the Ad Libitum Session as measured by responses to the Future Intent to Use questionnaire (visual analog scale range of "Definitely Would Not" to "Definitely Would")
Measure: Subject effects as measured by the Future Intent to Use questionnaire Time: 480 minutesDescription: Subjective product assessments during the PK Session as measured by responses to the Urge to Vape questionnaire (visual analog scale range of "Not at All" to "Extreme")
Measure: Subject effects as measured by the Urge to Vape questionnaire Time: 120 minutesDescription: Subjective product assessments during the PK Session as measured by responses to the Product Liking questionnaire (visual analog scale range of "Not at All" to "Extremely")
Measure: Subject effects as measured by the Product Liking questionnaire Time: 120 minutesDescription: Heart rate measurements during the Ad Libitum Session
Measure: Physiologic effects as measured by heart rate Time: 480 minutesDescription: Heart rate measurements during the PK Session
Measure: Physiologic effects as measured by heart rate Time: 120 minutesDescription: Blood pressure measurements during the Ad Libitum Session
Measure: Physiologic effects as measured by blood pressure Time: 480 minutesDescription: Blood pressure measurements during the PK Session
Measure: Physiologic effects as measured by blood pressure Time: 120 minutesDescription: Change in weight of study products during the Ad Libitum Session
Measure: Study product use Time: 480 minutesDescription: Number of requests to use the study products during the Ad Libitum Session
Measure: Study product use Time: 480 minutesDescription: Number of puffs taken from the study products during the Ad Libitum Session topography assessment
Measure: Study product use Time: 60 minutesDescription: Duration of puffs taken from the study products during the Ad Libitum Session topography assessment
Measure: Study product use Time: 60 minutesDescription: Volume of puffs taken from the study products during the Ad Libitum Session topography assessment
Measure: Study product use Time: 60 minutesDescription: Flow rate of puffs taken from the study products during the Ad Libitum Session topography assessment
Measure: Study product use Time: 60 minutesDescription: Inter-puff interval of puffs taken from the study products during the Ad Libitum Session topography assessment
Measure: Study product use Time: 60 minutesDescription: Change in weight of study products during the PK Session
Measure: Study product use Time: 5 minutesDescription: Number of puffs taken from the study products during the PK Session
Measure: Study product use Time: 5 minutesDescription: Incidence of product-use emergent adverse events
Measure: Safety and tolerability Time: 24 hoursDescription: Incidence of product malfunction or misuse
Measure: Safety and tolerability Time: 24 hoursThis study is being conducted to evaluate nicotine uptake and exposure, the abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system ENDS with tobacco- and menthol-flavored e-liquids in current smokers.
Description: PK Session baseline-adjusted maximum plasma nicotine concentration [Cmax]
Measure: Nicotine Uptake Time: 120 minutesDescription: PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-120)]
Measure: Nicotine Uptake Time: 120 minutesDescription: PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-15)]
Measure: Nicotine Uptake - PK Session Time: 15 minutesDescription: PK Session time of the maximum post-baseline nicotine concentration [Tmax]
Measure: Nicotine Uptake - PK Session Time: 120 minutesDescription: Ad Libitum Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-480)]
Measure: Nicotine Uptake - Ad Libitum Session Time: 480 minutesDescription: Subjective product assessments during the Ad Libitum Session as measured by responses to the Modified Product Evaluation Scale (scale range of 1 [not at all] to 7 [extremely]
Measure: Subjective Effects as measured by the Modified Product Evaluation Scale Time: 480 minutesDescription: Subjective product assessments during the Ad Libitum Session as measured by responses to the Future Intent to Use questionnaire (visual annalog scale range of "Definitely Would Not" to " Definitely Would")
Measure: Subjective effects as measured by the Future Intent to Use questionnaire Time: 480 minutesDescription: Subjective product assessments during the PK Session as measured by responses to the Urge to Smoke questionnaire (visual analog scale range of "Not at All" to "Extreme")
Measure: Subjective Effects as measured by the Urge to Smoke questionnaire Time: 120 minutesDescription: Subjective product assessments during the PK Session as measured by responses to the Product Liking questionnaire (visual analog scale range of "Not at All" to "Extremely")
Measure: Subjective Effects as measured by the Product Liking questionnaire Time: 120 minutesDescription: Heart rate measurements during the Ad Libitum Session
Measure: Physiologic effects as measured by heart rate Time: 480 minutesDescription: Heart rate measurements during the PK Session
Measure: Physiologic effects as measured by heart rate Time: 120 minutesDescription: Blood pressure measurements during the Ad Libitum Session
Measure: Physiologic effects as measured by blood pressure Time: 480 minutesDescription: Blood pressure measurements during the PK Session
Measure: Physiologic effects as measured by blood pressure Time: 120 minutesDescription: Change in exhaled carbon monoxide during the PK Session
Measure: Carbon Monoxide Exposure Time: 25 minutes (50 minutes for the nicotine gum period)Description: Change in weight of the RELX study products during the Ad Libitum Session
Measure: Study Product Use Time: 480 minutesDescription: Number of requests to use the study products during the Ad Libitum Session (requests to use the RELX ENDS product, number of cigarettes smoked, number of pieces of gum used)
Measure: Study Product Use Time: 480 minutesDescription: Number of puffs taken from the RELX ENDS and cigarette during the Ad Libitum Session topography assessment
Measure: Study Product Use Time: 60 minutesDescription: Duration of puffs taken from the RELX ENDS and cigarette during the Ad Libitum Session topography assessment
Measure: Study Product Use Time: 60 minutesDescription: Volume of puffs taken from the RELX ENDS and cigarette during the Ad Libitum Session topography assessment
Measure: Study Product Use Time: 60 minutesDescription: Flow rate of puffs taken from the RELX ENDS and cigarette during the Ad Libitum Session topography assessment
Measure: Study Product Use Time: 60 minutesDescription: Inter-puff interval of puffs taken from the RELX ENDS and cigarette during the Ad Libitum Session topography assessment
Measure: Study Product Use Time: 60 minutesDescription: Pre- to post-use RELX pod weight difference during the PK Session
Measure: Study Product Use Time: 5 minutesDescription: Number of puffs from the RELX ENDS and cigarettes during the PK Session
Measure: Study Product Use Time: 5 minutesDescription: Incidence of product-use emergent adverse events
Measure: Incidence of product-use emergent adverse events [Safety and Tolerability] Time: 24 hoursDescription: Incidence of product malfunction or misuse of the RELX ENDS
Measure: Incidence of product malfunction or misuse of the RELX ENDS [Safety and Tolerability] Time: 24 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports